Leflunomide Tillomed (Leflunomide)

Leflunomide is converted in the body to an active metabolite called teriflunomide. This metabolite blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo synthesis of pyrimidine nucleotides. By limiting pyrimidine production, the drug reduces the proliferation of activated T‑lymphocytes, thereby dampening the autoimmune inflammation that characterises rheumatoid and psoriatic arthritis.

The appropriate dose of Leflunomide Tillomed is determined by the prescribing physician based on the individual patient's clinical condition, disease severity, and laboratory monitoring. Dosage decisions consider factors such as liver function, blood pressure, and potential drug interactions. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations. Women of child‑bearing potential must use reliable contraception before, during, and for a specified period after stopping therapy. The drug is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements if applicable) and assist with import documentation.

Leflunomide differs from other conventional DMARDs such as methotrexate or sulfasalazine in its mechanism; it specifically inhibits pyrimidine synthesis rather than folate metabolism. Clinically, it offers an oral alternative with a once‑daily dosing schedule, but it carries a distinct safety profile, including a higher risk of liver enzyme elevations and teratogenicity. Choice of therapy depends on patient‑specific factors and physician judgment.

Leflunomide Tillomed should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and direct sunlight. Do not store in a refrigerator or freezer, and ensure the container remains tightly closed when not in use to maintain stability.

Leflunomide Tillomed is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. The medication is swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and should not crush, split, or chew the tablet unless specifically instructed.

The most serious risks of Leflunomide include severe liver injury, which can progress to hepatic failure, and teratogenic effects that can cause birth defects if exposure occurs during pregnancy. Additional serious concerns are bone‑marrow suppression leading to pancytopenia, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and opportunistic infections due to immunosuppression. Regular monitoring helps mitigate these risks.

Leflunomide Tillomed is contraindicated in pregnant women, women planning to become pregnant, and nursing mothers. Patients with pre‑existing severe liver disease, uncontrolled hypertension, or active infections should avoid the drug. Additionally, individuals taking certain interacting medications—such as warfarin, carbamazepine, or azathioprine—should not use Leflunomide unless a healthcare professional determines that benefits outweigh the risks.